Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages e517-e526

  Ishitsuka, Kenji ^a   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; ALPHA INTERFERON; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FORODESINE; LENALIDOMIDE; MOGAMULIZUMAB; PANOBINOSTAT; PRALATREXATE; RUXOLITINIB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE TRANSMISSION; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; OVERALL SURVIVAL; PARAPLEGIA; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; RISK FACTOR; SEXUAL TRANSMISSION; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS LOAD; ADULT; CANCER STAGING; COMPLICATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HTLV-I INFECTIONS; ISOLATION AND PURIFICATION; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TRANSMISSION; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84908118594     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70202-5     Document Type: Review

References (80)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:7415-7419.
3. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
4. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1:1031-1032.
5. Araya N, Sato T, Yagishita N, et al. Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease. Viruses 2011, 3:1532-1548.
6. Enose-Akahata Y, Abrams A, Johnson KR, Maloney EM, Jacobson S Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica. Blood 2012, 119:2829-2836.
7. Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000, 165:7278-7284.
8. Iwanaga M, Watanabe T, Yamaguchi K Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol 2012, 3:322.
9. Kaplan JE, Osame M, Kubota H, et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990, 3:1096-1101.
10. Shimoyama M Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991, 79:428-437.
11. Shimoyama M Chemotherapy of ATL. Adult T-cell leukemia 1994, 221-237. Oxford University Press, Oxford. K. Takatsuki (Ed.).
12. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
13. Van Dooren S, Salemi M, Vandamme AM Dating the origin of the African human T-cell lymphotropic virus type-i (HTLV-I) subtypes. Mol Biol Evol 2001, 18:661-671.
14. de Thé G, Bomford R An HTLV-I vaccine: why, how, for whom?. AIDS Res Hum Retroviruses 1993, 9:381-386.
15. Gessain A, Cassar O Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012, 3:388.
16. Satake M, Yamaguchi K, Tadokoro K Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012, 84:327-335.
17. Carneiro-Proietti AB, Sabino EC, Leão S, et al. Human T-lymphotropic virus type 1 and type 2 seroprevalence, incidence, and residual transfusion risk among blood donors in Brazil during 2007-2009. AIDS Res Hum Retroviruses 2012, 28:1265-1272. the NHLBI Retrovirus Epidemiology Donor Study-II (Reds-II), the NHLBI Retrovirus Epidemiology Donor Study-II (Reds-II)the NHLBI Retrovirus Epidemiology Donor Study-II (Reds-II), International ComponentInternational Component.
18. Laperche S, Worms B, Pillonel J Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009, 96:104-110. the European Network of Transfusion Medicine Societies, the Steering Committeethe Steering Committee.
19. Malm K, Ekermo B, Hillgren K, Britton S, Fredlund H, Andersson S Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scand J Infect Dis 2012, 44:852-859.
20. Prinsze FJ, Zaaijer HL The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands. Vox Sang 2012, 102:198-203.
21. Tajima K, Tominaga S, Suchi T, et al. Epidemiological analysis of the distribution of antibody to adult T-cell leukemia-virus-associated antigen: possible horizontal transmission of adult T-cell leukemia virus. Gann 1982, 73:893-901.
22. Sarin PS, Aoki T, Shibata A, et al. High incidence of human type-C retrovirus (HTLV) in family members of a HTLV-positive Japanese T-cell leukemia patient. Proc Natl Acad Sci USA 1983, 80:2370-2374.
23. Okochi K, Sato H, Hinuma Y A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984, 46:245-253.
24. Moriuchi H, Masuzaki H, Doi H, Katamine S Mother-to-child transmission of human T-cell lymphotropic virus type 1. Pediatr Infect Dis J 2013, 32:175-177.
25. Akagi T, Ono H, Shimotohno K Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus type 1. Blood 1995, 86:4243-4249.
26. Lairmore MD, Silverman L, Ratner L Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene 2005, 24:6005-6015.
27. Matsuoka M, Jeang KT Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280.
28. Satou Y, Yasunaga J, Yoshida M, Matsuoka M HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006, 103:720-725.
29. Zhao T, Satou Y, Sugata K, et al. HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator. Blood 2011, 118:1865-1876.
30. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004, 126:81-84.
31. Yamagishi M, Nakano K, Miyake A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012, 21:121-135.
32. Umino A, Nakagawa M, Utsunomiya A, et al. Clonal evolution of adult T-cell leukemia/lymphoma takes place in the lymph nodes. Blood 2011, 117:5473-5478.
33. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/lymphoma. Clin Cancer Res 2009, 15:30-38.
34. Okayama A, Stuver S, Matsuoka M, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 2004, 110:621-625.
35. Demontis MA, Hilburn S, Taylor GP Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses 2013, 29:359-364.
36. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010, 116:1211-1219. the Joint Study on Predisposing Factors of ATL Development investigators.
37. Hodson A, Laydon DJ, Bain BJ, Fields PA, Taylor GP Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma. Haematologica 2013, 98:385-388.
38. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002, 99:1505-1511.
39. Roncador G, Garcia JF, Garcia JF, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 2005, 19:2247-2253.
40. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007, 120:2052-2057.
41. Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance--related protein predicts poor outcome in adult T-cell leukemia. Blood 2001, 98:1160-1165.
42. Ishitsuka K, Kunami N, Katsuya H, et al. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett 2012, 317:218-225.
43. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007, 25:5458-5464. the Japan Clinical Oncology Group Study JCOG9801.
44. Jo T, Ishida T, Takemoto S, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 8506.
45. Hodson A, Crichton S, Montoto S, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol 2011, 29:4696-4701.
46. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009, 27:453-459.
47. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988, 6:128-141.
48. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003, 77:164-170. the Lymphoma Study Group of the Japan Clinical Oncology Group.
49. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001, 113:375-382.
50. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:182-186.
51. Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 2012, 30:1635-1640.
52. Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115:4337-4343.
53. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995, 332:1744-1748.
54. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995, 332:1749-1751.
55. Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002, 3:276-282. the French ATL therapy group.
56. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001, 113:779-784.
57. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001, 40:287-294.
58. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28:4177-4183.
59. Ishitsuka K, Katsuya H, Toyota T, et al. Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients. Int J Hematol 2010, 92:762-764.
60. Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999, 23:87-89.
61. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005, 19:829-834.
62. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
63. Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012, 119:2141-2148.
64. Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012, 120:1734-1741.
65. Nakamura T, Oku E, Nomura K, et al. Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute. Int J Hematol 2012, 96:657-663.
66. Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res 2004, 64:391-399.
67. Tamai Y, Hasegawa A, Takamori A, et al. Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2013, 190:4382-4392.
68. Narita T, Ishida T, Masaki A, et al. HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2014, 192:940-947.
69. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003, 9:3625-3634.
70. Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010, 16:1520-1531.
71. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
72. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012, 30:837-842.
73. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008, 14:1343-1350.
74. Uike N, Ogura M, Imaizumi Y, et al. Multicenter phase I dose-escalation study of lenalidomide in patients with relapsed adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL). Blood (ASH Annual Meeting Abstracts) 2012, 120. abstr 2737.
75. Lunning MA, Gonsky J, Ruan J, et al. Pralatrexate in relapsed/refractory HTLV-1 associated adult T-cell lymphoma/leukemia: a New York city multi-institutional experience. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstr 2735.
76. Ishitsuka K, Tsukasaki K, Tamura K Interferon alfa and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma. Drugs Today (Barc) 2011, 47:615-623.
77. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113:6528-6532.
78. Ishitsuka K, Tamura K Treatment of adult T-cell leukemia/lymphoma: past, present and future. Eur J Haematol 2008, 80:185-196.
79. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994. A predictive model for aggressive non-Hodgkin's lymphoma.
80. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474-2479. the Intergruppo Italiano Linfomi.